Evelyn Partners Group Ltd’s Bio-Rad Laboratories Class A BIO Stock Holding History

Evelyn Partners Group Ltd’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.93K	Buy	+27	New	+$7.66K	﹤0.01%	489

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Evelyn Partners Group Ltd's BIO Position: Q2 2026 in Review

Evelyn Partners Group Ltd opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 27 shares worth $7.93K. The stake represents ﹤0.01% of the portfolio and ranks #489 among its holdings.

181 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Evelyn Partners Group Ltd held 27 shares of Bio-Rad Laboratories Class A worth $7.93K as of Q2 2026.
Bio-Rad Laboratories Class A was a new Evelyn Partners Group Ltd position in Q2 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Evelyn Partners Group Ltd's portfolio in Q2 2026, its #489 holding.
181 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Evelyn Partners Group Ltd's 13F filing for Q2 2026, filed 7 Aug 2026.